Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

WALTHAM, Mass., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.  Total revenue for the second quarter was $7,307,000 compared to total revenue of $5,421,000 for the second quarter of fiscal year 2010, an increase of $1,886,000 or 35%.  Bioprocessing product revenue for the second quarter was $4,416,000 compared to $2,742,000 for the second quarter of fiscal 2010, an increase of $1,674,000 or 61%.  Royalty and research revenue for the second quarter, which consisted primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia®, was $2,891,000 compared to $2,679,000 for the same quarter in the prior year.

Operating expenses for the second quarter were $6,780,000 compared to $6,627,000 for the second quarter of fiscal year 2010.  Net income for the second quarter was $623,000 or $0.02 per diluted share, compared to a net loss for the second quarter of fiscal year 2010 of $980,000 or $0.03 per diluted share.  Cash, cash equivalents and marketable securities as of September 30, 2010 were $59,691,000 compared to $59,146,000 as of March 31, 2010.

"We are pleased to have achieved strong growth in our bioprocessing business for the quarter," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We are focused on completing our Phase 3 study for pancreatic imaging and our Phase 2b study for bipolar depression, and we look forward to reporting the top-line results for both of these studies in the first quarter of 2011."

For the six-month period ended September 30, 2010, total revenue was $14,317,000 compared to $10,481,000 for the same period in fiscal year 2010.  Operating expenses for the six-month period ended September 30, 2010 were $12,901,
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 21, 2014 2014 Deep ... professional and in-depth research report on the transformer ... definition, classification, application, and industry chain structure as ... international market analysis, including China’s domestic market as ... & economic situation analysis. The report also covers ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE ... of vaccines in China, announced today that,China,s Vice Premier, ... State Council, Ma Kai; Head of General Administration of,Quality ... Health, Chen Zhu; Vice Minister of Ministry of Science ...
... , NEW YORK, June 2 Delcath Systems, Inc. ... testing its proprietary treatment method for primary and metastatic ... States Food and Drug Administration ("FDA") granted Delcath,s application ... treatment of patients with neuroendocrine tumors. , , ...
... MOUNTAIN VIEW, Calif., June 2 VIVUS, Inc. (Nasdaq: ... next-generation therapies to address unmet needs in obesity, diabetes ... be featured in two podium presentations during the 69th ... held from June 5-9, 2009 in New Orleans, Louisiana. ...
Cached Biology Technology:China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation 2China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation 3Delcath Systems Granted Third Orphan Drug Designation 2Delcath Systems Granted Third Orphan Drug Designation 3Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 2Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting 3
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... -- Microbes living at the bottom of the Gulf of ... the Deepwater Horizon oil spill than previously thought, according to ... A paper on that research, conducted before the Deepwater ... a forthcoming issue of the journal Deep-Sea Research II ...
... cells live ever on the verge of suicide, requiring ... prevent the cells from pulling the trigger. This self-destructive ... dangerous precancerous cells are permitted to kill themselves, but ... that store memories, for instance. Rockefeller University scientists are ...
... [Brown University] Living with HIV is difficult under ... virus, alcohol consumption can become particularly perilous in intricate ... the Brown Alcohol Research Center on HIV (ARCH) funded ... Institutes of Health, Brown University scientists will study the ...
Cached Biology News:Microbes may consume far more oil-spill waste than earlier thought 2'Reaper' protein strikes at mitochondria to kill cells 2$7.5M grant to fund research on interaction of drinking and HIV infection 2$7.5M grant to fund research on interaction of drinking and HIV infection 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... a cytochrome P450 (CYP450) metabolite postulated to ... and cerebral vasculature. In rat cerebral microvessels, ... autoregulatory vasoconstriction. 20-HETE is excreted mainly as ... 20-HETE (20-40 pg/ml in human urine) is ...
... enables you to insert a transposable element ... by in vitro transposition. It uses TnsABC* ... the DNA target. Target DNA may be ... depending on your interests (6-8). If the ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: